PharmaXcelerate brings together leaders across pharma, biotech and life sciences to exchange insights, spark partnerships and shape what’s next.
"What I’ve learned designing and operating facilities across different manufacturing environments is that there is no one-size-fits-all solution. Each modality brings its own unique technical, regulatory, and operational challenges that need to be considered early in the design."
“The industry is actively transforming manufacturing through connected PAT ecosystems - where AI, digital twins, and predictive analytics are enabling real-time process understanding and improved product quality.”
Artificial intelligence is no longer a future conversation for life sciences. In this exclusive PharmaXcelerate USA 2026 interview, Gisèle Fahmi explores how organizations can accelerate AI adoption, modernize compliance, build trusted data ecosystems and prepare their workforce for the next era of pharmaceutical manufacturing and quality operations.
The Tabuk Pharmaceuticals–Biocon partnership is a particularly strong example, with the agreement including an option for technology transfer that could enable future localisation of GLP-1 manufacturing in the region.
MENA’s pharmaceutical industry is entering a new era. From Saudi Arabia’s manufacturing investments to the UAE’s growing role as a regional hub, the region is moving beyond pharmaceutical imports and building the infrastructure, capabilities and expertise needed to manufacture more complex medicines locally.
The future of sterile fill-finish is becoming faster, smarter and more automated. Jubilant Pharmova’s latest FDA-cleared isolator-based manufacturing line in Spokane highlights how advanced technology is helping the industry expand injectable production while strengthening sterility assurance, flexibility and quality.
A simple blood test could change how Alzheimer’s disease is detected and assessed. Roche and Eli Lilly’s newly FDA-cleared pTau217 test brings blood-based biomarker testing one step closer to routine clinical care, potentially making Alzheimer’s assessment more accessible, scalable and less invasive.
We are deeply involved in MDM topics and projects in especially the German pharmaceutical industry and thus this was a perfect event to get to know to the network. The right people are here. MDM leads, department heads and the exchanges we have are very high quality.
The presentations have been really excellent. We've seen a lot of different experiences from larger and smaller companies at different stages in their data management journey. AI has been a really big topic at this year's meeting.
It's a very good audience. It's a small event but a very good quality event. So it's really important that we're here to engage with people who are seeking solutions especially when it comes to MDM and data governance.
Discover the key moments from the 11th Annual Master Data and Data Governance Excellence in Life Sciences conference. Industry professionals gathered in Berlin to exchange insights, share best practices, and discuss how robust Master Data Management and Data Governance strategies are enabling greater efficiency, compliance, and innovation throughout the life sciences sector.
Watch the highlights from the 5th Annual Cleanroom Design & Engineering Forum, where international experts and industry leaders came together to discuss sustainability, energy efficiency, cleanroom innovation and the future of pharmaceutical and controlled-environment facilities. The event featured insightful presentations, engaging discussions and valuable networking opportunities that reflected the evolving priorities of the cleanroom industry.
At MDM LS Berlin 2025, James Keirstead reflected on the quality and diversity of presentations, highlighting the range of perspectives shared across organizations at different stages of their master data management journey. He noted the strong focus on AI throughout the event, emphasizing that the conversation goes beyond technical implementation. Alongside the technology itself, there is growing interest in the organizational, cultural and non-technical dimensions that shape successful adoption and impact within life sciences.
At MDM LS Berlin 2025, Flavio Fessia presented on the importance of establishing a commercial data governance framework within the evolving field of robotic-assisted surgery. He highlighted the industry’s transition from traditional medical devices toward MedTech, where data is becoming an increasingly critical driver of value, particularly in commercial applications. In this context, he emphasized that a strong governance framework is essential to enable scalability, support innovation, and ensure success in this rapidly advancing space.
At MDM LS Berlin 2025, Sandeep Murali highlighted the value of cross-functional exchange within the life sciences industry. He emphasized how valuable it is to observe the diversity of approaches across both large pharmaceutical organizations and their ecosystem of partners.
